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BACKGROUND: It remains important to understand the biology and identify biomarkers for less studied cancers like testicular cancer.
The purpose of this study was to determine the methylation frequency of several cancer-related genes in different histological types
of testicular cancer and normal testis tissues (NT).
METHODS: DNA was isolated from 43 seminomas (SEs), 14 non-SEs (NSEs) and 23 NT, and was assayed for promoter methylation
status of 15 genes by quantitative methylation-specific PCR. The methylation status was evaluated for an association with cancer, and
between SEs and NSEs.
RESULTS: We found differential methylation pattern in SEs and NSEs. MGMT, VGF, ER-b and FKBP4 were predominately methylated in
NSEs compared with SEs. APC and hMLH1 are shown to be significantly more methylated in both subtypes in comparison with NT.
When combining APC, hMLH1, ER-b and FKBP4, it is possible to identify 86% of the NSEs, whereas only 7% of the SEs.
CONCLUSIONS: Our results indicate that the methylation profile of cancer-associated genes in testicular cancer correlates with
histological types and show cancer-specific pattern for certain genes. Further methylation analysis, in a larger cohort is needed to
elucidate their role in testicular cancer development and potential for therapy, early detection and disease monitoring.
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Testicular cancer is the most commonly diagnosed malignancy
among young men aged 15 to 40 years, and its incidence has
doubled in the past 40 years (Chia et al, 2010). An annual increase
of 3–6% is reported for Caucasian populations. In the United
States, approximately 8500 newly diagnosed testicular cancer cases
and 350 deaths were expected in 2010 (Jemal et al, 2010). Testicular
germ cell tumours (TGCTs) represent over 95% of the testicular
cancers and histopathologically are classified into two major
groups of seminomas (SE) or non-SEs (NSE), frequently occurring
as mixed tumours (Holmes et al, 2008). Histologically, SE
resembles primordial germ cells/gonocytes, whereas NSE shows
somatic, primitive embryonal or extra-embryonal differentiation
(Horwich et al, 2006). Carcinoma in situ or intra-tubular germ cell
neoplasia unclassified are believed to be the origin of both SE and
NSE (Rajpert-De Meyts, 2006). They have a primordial germ cell/
gonocyte origin, and it is important to emphasise that epigenetic
reprogramming is known to occur during germ cells development.
The treatment of testicular cancer includes orchiectomy, and
according to the metastatic condition surveillance, or adjuvant
retroperitoneal surgery, radiation and chemotherapy are offered.
The decision whether to choose the adjuvant treatment regimen
is based only on clinical parameters, leading to around 25%
development of metastasis in patients on surveillance or
unnecessary adjuvant treatments in 20% of the patients. Genetic
understanding of each tumour will enable to better tailor the
treatment.
The importance of epigenetic alterations has long been
demonstrated in carcinogenesis. Several studies have shown that
methylation-associated silencing inactivates certain tumour
suppressor genes (TSGs) as effectively as mutations and is one
of the cancer-predisposing hits described in Knudson’s two hit
hypothesis. Promoter methylation, the most studied epigenetic
alteration, is also increasingly recognised as a major mechanism of
gene inactivation during TGCT progression (Manton et al, 2005;
Ellinger et al, 2009). CG dinucleotide-rich regions, also known as
CpG islands, in or near the proximal promoter regions of genes are
targets for DNA methylation, leading to effective transcriptional
silencing (Herman, 1999). In normal cells, CpG methylation is an
important mechanism for regulating gene expression, whereas in
cancer cells, aberrant promoter methylation (hypermethylation)
can lead to abnormal gene silencing, including repression of TSGs.
Another relevant aspect is that environmental and endogenous
conditions can influence the epigenetic processes. The exposure to
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certain environmental risk factors may be related to the onset of
cancer or to participate in carcinogenesis (Brait et al, 2009). There
are many evidences that endogenous factors (such as oestrogens or
androgens inhibitors) exposure may lead to cancer (Godmann
et al, 2009), and endogenous factors (like hormonal stimuli)
induce methylation of promoter region of certain genes (Kutanzi
et al, 2010). Even though TGCT has high survival rates due to good
responses to therapy, significant consequences of multimodality
therapies exist with regard to general health, secondary late
malignancies, reproduction and economic productivity (Sokoloff
et al, 2007). A great need for understanding TGCT biology still
exists to help curb its increasing incidence and potentially adopt
effective prevention strategies.
Several genetic alterations have been shown in TGCTs.
For example, abnormalities in the short arm of chromosome
12 (Mostert et al, 1998), as well as loss on chromosomes 1, 3, 5, 9,
11, 12q, 13q, 17p and 18q (Mathew et al, 1994; Lothe et al, 1995;
al-Jehani et al, 1995; Honorio et al, 2003; Oosterhuis and
Looijenga, 2005) have been reported. But major TSGs having a
role in TGCTs are yet to be identified (Honorio et al, 2003). One of
the most intriguing questions in the biology of TGCTs is how such
distinct histological tumour subtypes (SE and NSE) can arise from
the same cell type (cell of origin). Both subtypes exhibit similar
cytogenetic abnormalities (Lutzker and Barnard, 1998). So far,
molecular alterations that could distinct SEs from NSEs have not
been clear yet. A pioneer study, performed in 1991, has shown
that hypermethylation was abundant in NSEs, but not in SEs
(Peltomaki, 1991). In 2002, Smiraglia et al (2002) demonstrated
significant epigenetic differences between SEs and NSEs by a global
methylation approach. In addition, studies of the X chromosome
have demonstrated little or no methylation in SEs, and increased
methylation in NSEs, particularly in more highly differentiated
NSEs (Looijenga et al, 1997). Netto et al (2008) analysed global
methylation status by immunohistochemistry and concluded that
SEs cells generally retain the lack of methylation that occurs due to
normal developmental erasure of methylation marks, whereas
NSEs do not, thus showing more methylation. This was
independently shown as well (Wermann et al, 2010).
In the present study, we used a candidate gene approach to
investigate the methylation profile of 57 primary TGCT (of which
43 were SEs and 14 were NSEs) and 23 normal testis (NT) by
quantitative methylation-specific PCR (QMSP). QMSP has been
successfully used in other tumour models and has the benefit of
providing accurate and precise data regarding the level of
methylation in the various tumours. Six of the genes we evaluated,
including ARF, APC, MGMT, RAR-b2, CCNA1 and hMLH1, were
previously shown to be aberrantly methylated in TGCT (Muller
et al, 2000; Koul et al, 2002; Honorio et al, 2003; Olasz et al, 2005;
Lind et al, 2007). The remaining nine genes we studied has been
found to be methylated in other cancer types, but not yet tested in
TGCT; these genes include AIM1, PGP9.5, S100A2, ER-a, ER-b,
MCAM, VGF, FKBP4 and SSBP2. Among the later genes, four genes
(MCAM, VGF, FKBP4 and SSBP2) were recently discovered by our
group, using a pharmacological unmasking strategy in other
cancer types (Hoque et al, 2008). We compared the promoter
methylation profiles of SEs and NSEs along with NT to better
understand the role of epigenetic silencing in testis tumouri-
genesis. Relationships between methylation values and clinico-
pathological parameters were further assessed.
MATERIALS AND METHODS
Study cohort
The TGCT and NT samples were retrospectively collected from the
Johns Hopkins Medical Institutions tissue archive. To be included
in the cohort, an eligible patient had to have a confirmed diagnosis
of TGCT (or normal tissue) and a sufficient amount of archived
tumour (or normal) material to allow for DNA extraction (tissue
preserved in sectioned blocks; 450% of tumour cells). A total of
75% (43 out of 57) of our TGCT samples were SEs and 25% (14 out
of 57) were NSEs. We also analysed 23 NT from archived samples
(testis removed on castration procedures). Thus, a total of 80
samples (57 tumours and 23 normals) were tested for methylation
pattern by QMSP. Demographic and clinical information was
obtained from the computerised tumour registry at the Johns
Hopkins Healthcare System. The tumours were classified accord-
ing to the WHO Classification of Tumours, Pathology and Genetics
of the Urinary System and Male Genital Organs (Looijenga, 2009).
Patient characteristics included in this study are summarised in
Table 1. Approval for research on human subjects was obtained
from the Johns Hopkins University Institutional Review Boards.
This study qualified for exemption under the US Department of
Health and Human Services policy for protection of human
subjects (45 CFR 46.101(b)) (IRB 03-11-12-06e).
Gene selection
A total of 15 genes were selected for promoter methylation status
analysis. Among these genes, six were previously assessed on
testicular tissues (ARF, CCNA1, MGMT, MLH1, APC and RAR-b2;
Muller et al, 2000; Koul et al, 2002; Honorio et al, 2003; Olasz et al,
2005; Lind et al, 2007), five were not yet tested in this tissue type
(AIM1, PGP9.5, S100, ER-a and ER-b; Fiegl et al, 2004; Brait et al,
2008; Carvalho et al, 2008), and four were recently identified genes
by our pharmacological unmasking strategy in different cancer
types (MCAM, VGF, FKBP4 and SSBP2) (Hoque et al, 2008).
DNA extraction
After initial patient de-identification, all original histological slides
from the TGCT or normal specimens were reviewed by a
pathologist to reconfirm the diagnosis. A representative block
was retrieved for DNA extraction. Microdissected NT samples
from autopsy material were used for controls. Histological slides
from the formalin-fixed, paraffin-embedded tissue were prepared.
Table 1 Demographic and clinical characteristics of testicular cancer
patients (N¼ 57, seminomas¼ 43, non-seminomas¼ 14) and normals
(N¼ 24)
Characteristic Number of patients (%)
Hystologic diagnosis Seminoma Non-seminoma Normal
Total samples 43 (100) 14 (100) 23 (100)
Site
Right 25 (58.1) 10 (71.4) 5 (21.7)
Left 18 (41.9) 4 (28.6) 3 (13.1)
Unknown 0 (0) 0 (0) 15 (65.2)
Age (years)
Median age (range) 34 (22–62) 27.5 (23–38) 55 (20–81)
Race
Caucasian 35 (81.4) 10 (71.4) 18 (78.3)
African American 4 (9.3) 2 (14.2) 5 (21.7)
Others 4 (9.3) 3 (21.4) 0 (0)
Stage
I 40 (93.0) 6 (42.9)
II 3 (7.0) 5 (35.7) N/Aa
III 0 (0) 3 (21.4)
aN/A¼Not applicable.
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Slides were microdissected to obtain 450% neoplastic cells. DNA
was extracted using standard protocols as previously described
(Brait et al, 2008). Briefly, DNA was obtained by digestion with
50mgml1 proteinase K (Roche, Indianapolis, IN, USA) in the
presence of 1% SDS at 48 1C for 2 days, followed by phenol/
chloroform extraction and ethanol precipitation, and finally
dissolved in 20 ml of LoTE (2.5mmol l1 EDTA and 10mmol l1
Tris-HCL) and stored at 20 1C until used.
Sodium bisulphite treatment
DNA extracted from tumour or normal tissue was subjected to
bisulphite treatment with the EpiTect Bisulfite kit (QIAGEN,
Valencia, CA, USA), according to the manufacturer’s instructions.
Treated DNA was stored at 80 1C until used.
Methylation analysis
Bisulphite-modified DNA was used as a template for fluorescence-
based real-time PCR, as previously described (Brait et al, 2009).
Amplification reactions were carried out in triplicate in a final
volume of 20 ml containing 1 ml of bisulfite-modified DNA, 600 nM
concentrations of forward and reverse primers, 200 nM probe, 0.6 U
of platinum Taq polymerase (Invitrogen, Frederick, MD, USA),
200mM concentrations each of dATP, dCTP, dGTP and dTTP, and
6.7mM MgCl2. Primers and probes were designed to specifically
amplify the promoters of the 15 genes of interest and the promoter
of a reference gene, b-actin; primer and probe sequences, and
annealing temperatures are provided in Supplementary Table 1.
Amplifications were carried out using the following profile: 95 1C
for 3min, followed by 50 cycles at 95 1C for 15 s and 60 1C for 1min.
Amplification reactions were carried out in 384-well plates in a
7900HT sequence detector (Applied Biosystems, Foster City, CA,
USA) and were analysed by a sequence detector system (SDS 2.3;
Applied Biosystems). Each plate included studied DNA samples,
positive (in-vitro methylated leukocyte DNA) and negative (normal
leukocyte DNA or DNA from a known unmethylated cell line) controls
and multiple water blanks. Leukocyte DNA from a healthy indivi-
dual was methylated in vitro with excess SssI methyltransferase
(New England Biolabs Inc., Beverly, MA, USA) to generate completely
methylated DNA, and serial dilutions (90–0.009 ng) of this DNA
were used to construct a calibration curve for each plate. All
samples were within the assay’s range of sensitivity and
reproducibility, based on the amplification of the internal
reference standard (threshold cycle (CT) value for b-actin of 40).
The relative level of methylated DNA for each gene in each sample
was determined as a ratio of methylation-specific PCR-amplified
gene to b-actin (reference gene), and then multiplied by 1000 for
easier tabulation (average value of triplicates of the gene of interest
divided by the average value of triplicates of b-actin  1000).
This measure represents the relative level of methylation in a
particular sample and was used for direct comparison of samples.
For a tumour sample to be considered methylated at a specific gene,
it had to meet two specific criteria. Amplification must have been
present in at least two of the three reaction wells in the triplicate
run, and the b-actin-normalised mean methylation value must have
fallen within the range of the serial standard curve dilutions. The
lack of DNA contamination was verified by the absence of ampli-
fication of a distilled water negative control for each QMSP run.
Statistical analysis
The primary objective in this study was to describe the
methylation patterns of 15 well-established or putative TSGs in
NT and two TGCT types, SE and NSE.
Gene methylation was treated as a continuous variable.
Univariate and multivariable logistic regression models were
constructed sequentially to examine the association of gene
methylation with the disease status (tumour vs normal). Odds
ratios (OR) were estimated with 95% confidence intervals (CI),
which quantified the strength of the association and its
uncertainty. The final model was selected by using the backward
selection method in multivariable logistic regression.
Correlation in methylation between genes was also examined so
as to aid in the selection of genes that independently contributed to
distinguishing tumour from normal samples (or the two subtypes:
SEs and NSEs). Receiver-operating characteristic (ROC) analyses
were conducted to evaluate the marker validity to differentiate
tumour and normal. Sensitivity, specificity and area under the
curve (AUC) were estimated along with 95% CI. Correlated ROC
curves were compared using DeLong’s method, which is a non-
parametric approach (DeLong et al, 1988).
On the basis of the correlations among all the 15 genes obtained
using a non-parametric approach along with the individual gene
performance, the genes shown to be independent of each other by
Spearman correlation test, were selected to be included in a logistic
regression model. This model was used to assess the probability of
tumour. The genes explored further for panel performance were
those with Po0.10 in the final model. Multi-variable logistic
regression was performed with genes of interest, as well as patient
characteristics (age, race and site), entered the model simulta-
neously and were eliminated by backwards selection. An associa-
tion was considered statistically significant with P-value o0.05.
All P-values reported are two-sided.
The optimal cutoff was determined as the point at which it
simultaneously maximised sensitivity and specificity. We used
cancer cases and NT samples for generating ROC curves
for individual genes, and the cut point of methylation values were
established with the values that optimally differentiate the two
sample groups. Representative ROC curves are available in
Supplementary Figure 1.
RESULTS
Patients with TGCT were aged between 22 and 62 years
(median¼ 33). Age range of controls was 20 to 81 (median¼ 55).
Patients with SE were aged between 22 and 62 years (median¼ 34),
and for NSE, were between 23 and 38 years (median¼ 27.5).
Control subjects were significantly older compared with patients
with overall TGCT (P¼ 0.05, Wilcoxon non-parametric test). The
samples include 46 stage-I TGCT and 11 Xstage-II TGCT. Thirty-
five TGCT analysed were from right site and 22 from left site. The
majority of the samples were obtained from Caucasian. Patient
characteristics included in this study are summarised in Table 1.
Overall methylation frequency in TGCTs
A total of 15 genes (AIM1, ARF, CCNA1, MGMT, hMLH1, PGP9.5,
S100A2, APC, RAR-b2, ER-a, ER-b, MCAM, VGF, FKBP4 and
SSBP2) were analysed for promoter methylation using QMSP in 57
tumour samples, comprising 43 SEs and 14 NSEs, and 23 NT
samples. The observed frequencies of each gene using optimal
cutoffs that maximised specificity and sensitivity are summarised
in Table 2.
VGF show a significant cancer-specific methylation (P¼ 0.008,
by Fisher’s exact test). A total of 14 out of 57 TGCT showed
methylation of the promoter region of VGF, whereas no
methylation was observed in NT. hMLH1 was significantly
methylated in TGCT (39% (22 out of 57)) in comparison with
normal (4% (1 out of 23)); P¼ 0.002, by Fisher’s exact test).
Methylation in SE and NT
A total of 15 genes (AIM1, ARF, CCNA1, MGMT, hMLH1, PGP9.5,
S100A2, APC, RAR-b2, E-Ra, ER-b, MCAM, VGF, FKBP4 and
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SSBP2) was analysed for promoter methylation in 23 NT and 43 SE
cases by QMSP. Results for all genes in all SE cases and controls
(NTs) are presented in Table 3a. Individual gene sensitivity and
specificity was determined on the basis of an empiric cutoff values
by maximising sensitivity and specificity, and the AUC values were
calculated for each gene. At least one TSG locus was methylated in
37 out of 43 SE cases (86%), and a total of 11 out of 43 (25.6%)
tumour samples showed methylation at three or more of the loci.
By a non-parametric statistical approach (DeLong’s method), we
determined the correlation of methylation events among all the 15
genes. By Spearman correlation test, eight genes (AIM1, CCNA1,
MCAM, PGP9.5, hMLH1, ARF, VGF and APC) showed to be
independent of each other and were selected to be included in a
logistic regression model, which predict the probability of tumour.
Patient characteristics (age, race and site) were included in the
multi-variable logistic regression model, together with the
previously mentioned eight genes. Smoking status and alcohol
consumption were not considered in this analysis, as there were
too many unknowns reported. Backward selection was used and
the significance level of staying in the final model was set at
Po0.10. Among all eight genes, only APC and MCAM remained
statistically significant and stayed in the final model (P¼ 0.057 and
P¼ 0.035, respectively) after controlling for patient characteristics
(age, race and site). We then grouped the independent genes in
different combinations (AIM1, CCNA1, MCAM, PGP9.5, hMLH1,
ARF, VGF and APC), considering optimal cutoffs that separated
both groups, and established the maximum possible specificity at
78%, and each combination had a slight different sensitivity, with
no significant improvement as shown in Table 3b.
Methylation in NSE and NT
The frequency of promoter methylation, including the cutoff
value at each gene included in this panel is listed in Tables 4a.
Briefly the methylation frequency were: AIM1 21%, ARF 0%,
CCNA1 14%, MCAM 71%, MGMT 50%, MLH1 71%, PGP9.5 14%,
S100A2 57%, SSBP2 57%, APC 50%, RAR-b2 21%, VGF 50%, ER-a
36%, ER-b 64% each and FKBP4 36%.
On the basis of the correlations among all the 15 genes obtained
using a non-parametric approach along with the individual gene
performance, six genes (APC, VGF, MGMT, hMLH1, ER-b and
FKBP4) were shown to be independent of each other and each of
them shows the strongest predictive potential representing the
corresponding cluster, and thus, were selected to be included in a
multivariable logistic regression model that modelled the prob-
ability of tumour. However, issues arose with such small sample
size, that is, for VGF, MGMT and FKBP4, the maximum likelihood
estimates are not possible, as there is no variation in methylation
values for NT samples (e.g., all normal samples had zero
methylation values for each of these three genes). Thus, only
hMLH1, APC and ER-b were considered in the multivariable
logistic model. It turned out that hMLH1 remained statistically
significant in this final model (P¼ 0.044), which indicated its
independent effect in predicting tumour. Performance of hMLH1
combined with APC and ER-b was explored as well. The
significance of hMLH1 was examined with adjustment for the
current available patient characteristics (age, race and site), using
the logistic regression model. The independent effect of the genes
of interest was evaluated with adjustment for age only. Results
indicated that association of hMLH1 hypermethylation with
Table 2 Promoter methylation frequency in TGCT and in normal
testicular samples
Genes Cutoff a
Number of tumors
with methylation/
total number
of tumors
(%, 95% CI)
Number of tumors
with methylation/
total number
of tumors
(%, 95% CI)
AIM1 44.817 3/57 (5, 1.1–14.6) 1/23 (4.3, 0.1–22.0)
ARF 0.3 2/57 (3.5, 0.4–12.1) 2/23 (8.7, 1.1–28.0)
CCNA1 8.173 5/57 (8.8, 2.9–19.3) 0/23 (0, 0–14.8)
MCAM 1073 23/57 (40.4, 27.6–54.2) 9/23 (39.1, 19.7–61.5)
MGMT 0.193 8/57 (14, 6.3–25.8) 0/23 (0, 0–14.8)
MLH1 0.096 22/57 (38.6, 26.0–52.4) 1/23 (4, 0.1–22.0)
PGP9 177.09 2/57 (3.5, 0.4–12.1) 0/23 (0, 0–14.8)
S100 858.15 23/57 (40.4, 27.6–54.2) 19/23 (83, 61.2–95.1)
SSBP2 623.99 8/57 (14, 6.3–25.8) 16/23 (69.5, 47.1 –86.8)
APC 19.077 7/57 (12.3, 5.1–23.7) 19/23 (83, 61.2–95.1)
RAR-b2 14.273 1/57 (1.8, 0–9.4) 0/23 (0, 0–14.8)
VGF 0.023 14/57 (24.6, 14.1–37.8) 0/23 (0, 0–14.8)
ER-a 72.072 6/57 (10.5, 4.0–21.5) 10/23 (43.5, 23.2 –65.5)
ER-b 10.145 13/57 (22.8, 12.7–35.8) 7/23 (30, 13.2–52.9)
FKBP4 35.001 7/57 (12, 5.1–23.7) 0/23 (0, 0–14.8)
Abbreviations: CI¼ confidence intervals; TGCT¼ testicular germ cell tumors. aThe
optimal cutoff was determined as the point at which it simultaneously maximized
sensitivity and specificity.
Table 3a Seminomas and normal testicular samples: (a) promoter
methylation frequency in seminomas and normal testicular samples
Seminoma Normal
Genes Cutoff
Number of tumors
with methylation/
total number of
tumors
(%, 95% CI)
Number of tumors
with methylation/
total number of
tumors
(%, 95% CI)
AIM1 44.817 0/43 (0, 0–8.2) 1/23 (4.3, 0.1–22.0)
ARF 0.3 5/43 (11.6, 3.9–25.1) 2/23 (8.7, 1.1–28.0)
CCNA1 8.173 2/43 (4.6, 0.6–15.8) 0/23 (0, 0–14.8)
MCAM 1073 14/43 (32.6, 19.1–48.5) 9/23 (39.1, 19.7–61.5)
MGMT 0.193 1/43 (2.3, 0.1– –12.3) 0/23 (0, 0–14.8)
MLH1 0.096 12/43 (27.9, 15.3–43.7) 1/23 (4, 0.1–22.0)
PGP9.5 177.09 4/43 (9.3, 2.6–22.1) 0/23 (0, 0–14.8)
S100 858.15 0/43 (0, 0–8.2) 19/23 (83, 61.2–95.1)
SSBP2 623.99 0/43 (0, 0–8.2) 16/23 (69.5, 47.1 –86.8)
APC 19.077 5/43 (11.6, 3.9–25.1) 19/23 (83, 61.2–95.1)
RAR-b2 14.273 1/43 (2.3, 0.1–12.3) 0/23 (0, 0–14.8)
VGF 0.023 7/43 (16.3, 6.8–30.7) 0/23 (0, 0–14.8)
ER-a 72.072 8/43 (18.6, 8.4–33.4) 10/23 (43.5, 23.2 –65.5)
ER-b 10.145 12/43 (27.9, 15.3–43.7) 7/23 (30, 13.2–52.9)
FKBP4 35.001 1/43 (2.3, 0.1–12.3) 0/23 (0, 0–14.8)
Table 3b Seminomas and normal testicular samples: (b) analysis of gene panels, based on logistic regression model, considering optimal cutoff for
differenciating both groups
Panel
Cutoff based on predictive
probability of tumora
Sensitivity,
% (95% CI)
Specificity,
% (95% CI)
AUC
(95% CI)
MCAM, APC 0.643971 76.7 (61.4–88.2) 78.3 (56.3–92.5) 0.81 (0.70–0.92)
MCAM, APC, MLH1 0.620704 79.1 (64.0–90.0) 78.3 (56.3–92.5) 0.84 (0.74–0.94)
MCAM, APC, MLH1, AIM1 0.601593 81.4 (66.6–91.6) 78.3 (56.3–92.5) 0.85 (0.75–0.95)
MCAM, APC, MLH1, AIM1, PGP9.5 0.590917 81.4 (66.6–91.6) 78.3 (56.3–92.5) 0.86 (0.76–0.95)
Abbreviations: AUC¼ area under the curve; CI¼ confidence interval. aPredictive probabilities were obtained from the logistic regression models.
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tumour remained positive (OR¼ 8.29; 95% CI¼ 0.66–103.5),
albeit no statistical significance (P¼ 0.100). Results should be
interpreted with caution with an imprecise estimate for strength of
association (i.e., wide CI for the OR estimate). Table 4b shows the
predictive performance of the three gene panels (hMLH1, APC and
ER-b), considering optimal cutoffs that separated both groups.
Supplementary Figure 2 illustrates the predictive powers of hMLH1
alone, as well as combination with APC and ER-b. There was no
statistically significant improvement with the combined genes
compared with hMLH1 alone, based on the non-parametric
approach of predictive power of DeLong et al (1988).
On the basis of the cutoff value determined for SE cases, six
genes (CCNA1, MGMT, PGP9.5, RAR-b2, VGF and FKBP4) showed
100% specificity (no methylation in NT) in NSE cases. From this
six genes, only one gene was methylated in 5 out of 14 (35.7%)
cases, two genes were methylated 4 out of 14 (28.5%) cases, one
sample showed methylation in three genes, 1 out of 14 (7.1%), and
only one sample showed methylation in four genes, 1 out of 14
(7.1%); no samples showed methylation in five genes, and one
sample out of 14 (7.1%) had all six genes methylated. At least one
of these six genes was observed methylated in 12 out of 14 (86%) of
the samples with 100% specificity for NSEs.
Methylation levels and frequency across sample types
When dividing the groups into normal, SEs and NSEs, one would
expect to see a differential methylation of the analysed genes, as
methylation is tissue specific and cancer specific. The non-
parametric test (DeLong’s method) was used to test for differential
methylation frequency (in a binary fashion), and five genes met
statistical significance (APC, MGMT, hMLH1, ER-b and FKBP4).
This test accounted for the normalised methylation level as a
continuous variable. MGMT, VGF, CCNA1 and FKBP4 are
interesting, as they could be specific for tumours as all of the
normal samples showed no methylation, and in addition, hMLH1
that had only one positive in normal. There was methylation in
normal, SE and NSE in similar frequencies for the following genes:
ARF, S100A2, SSBP2, ER-a and ER-b. Interestingly, SSBP2 and ER-a
showed higher levels and frequency of methylation seen in the
normal samples than in SE and NSE.
As supported by the previous studies (Peltomaki, 1991;
Smiraglia et al, 2002; Netto et al, 2008), we found differential
methylation pattern in SE and NSE. MGMT, VGF, ER-b and FKBP4
are predominately methylated in NSEs when compared with SEs.
APC and hMLH1 are shown to be methylated in both subtypes, but
APC exhibits not only a higher frequency, but also higher levels,
and hMLH1 a significantly higher frequency. When combining
APC, hMLH1, ER-b and FKBP4 (considering empiric cutoffs), it is
possible to identify 86% of the NSEs, whereas only 7% of the SEs
(AUC 0.90 (0.81–1.00)).
The summary data for the comparison of SEs and NSEs is in
Table 5a and b Representative scatter plots of methylation of the 15
Table 4a Non-seminomas and normal testicular samples: (a) promoter
methylation frequency in non-seminomas and normal testicular samples
Non-seminoma Normal
Genes Cutoff
Number of tumors
with methylation/
total number of
tumors
(%, 95% CI)
Number of tumors
with methylation/
total number of
tumors
(%, 95% CI)
AIM1 44.817 3/14 (21.4, 4.7–50.8) 1/23 (4.3, 0.1–22.0)
ARF 0.3 0/14 (0, 0- 6.9) 2/23 (8.7, 1.1–28.0)
CCNA1 8.173 2/14 (14.3, 1.8–42.8) 0/23 (0, 0–14.8)
MCAM 1073 10/14 (71.4, 41.9–91.6) 9/23 (39.1, 19.7–61.5)
MGMT 0.193 7/14 (50, 23.0–77.0) 0/23 (0, 0–14.8)
MLH1 0.096 10/14 (71.4, 41.9–91.6) 1/23 (4, 0.1–22.0)
PGP9 177.09 2/14 (14.3, 1.8–42.8) 0/23 (0, 0–14.8)
S100 858.15 8/14 (57.1, 28.9–82.3) 19/23 (83, 61.2–95.1)
SSBP2 623.99 8/14 (57.1, 28.9–82.3) 16/23 (69.5, 47.1 –86.8)
APC 19.077 7/14 (50, 23.0–77.0) 19/23 (83, 61.2–95.1)
RAR-b2 14.273 3/14 (21.4, 4.7–50.8) 0/23 (0, 0–14.8)
VGF 0.023 7/14 (50, 23.0–77.0) 0/23 (0, 0–14.8)
ER-a 72.072 5/14 (35.7, 12.8–64.9) 10/23 (43.5, 23.2 –65.5)
ER-b 10.145 9/14 (64.3, 35.1–87.2) 7/23 (30, 13.2–52.9)
FKBP4 35.001 5/14 (35.7, 12.8–64.9) 0/23 (0, 0–14.8)
Abbreviation: CI¼ confidence interval.
Table 4b Non-seminomas and normal testicular samples: (b) analysis of
gene panels, based on logistic regression model, considering optimal cutoff
for differentiating both groups
Combined
genes
Cutoff
based on
predictive
probability
of tumora
Sensi-
tivity (%)
Speci-
ficity (%)
AUC
(95% CI)
MLH1, APC,
and ER-b
0.225668 85.7 (57.2 – 98.2) 82.6 (61.2 – 95.1) 0.89 (0.75 – 1.00)
Abbreviations: AUC¼ area under the curve; CI¼ confidence interval. aPredictive
probabilities were obtained from the logistic regression models.
Table 5a Seminomas and non-seminoma testicular samples: (a)
promoter methylation frequency in seminomas and non-seminoma
testicular samples
Non-seminoma Seminoma
Genes Cutoff
Number of tumors
with methylation/
total number
of tumors
(%, 95% CI)
Number of tumors
with methylation/
total number
of tumors
(%, 95% CI)
AIM1 44.817 3/14 (21.4, 4.7–50.8) 0/43 (0, 0–8.2)
ARF 0.3 0/14 (0, 0–6.9) 5/43 (11.6, 3.9–25.1)
CCNA1 8.173 2/14 (14.3, 1.8–42.8) 2/43 (4.6, 0.6–15.8)
MCAM 1073 10/14 (71.4, 41.9–91.6) 14/43 (32.6, 19.1–48.5)
MGMT 0.193 7/14 (50, 23.0–77.0) 1/43 (2.3, 0.1–12.3)
MLH1 0.096 10/14 (71.4, 41.9–91.6) 12/43 (27.9, 15.3–43.7)
PGP9 177.09 2/14 (14.3, 1.8–42.8) 4/43 (9.3, 2.6–22.1)
S100 858.15 8/14 (57.1, 28.9–82.3) 0/43 (0, 0–8.2)
SSBP2 623.99 8/14 (57.1, 28.9–82.3) 0/43 (0, 0–8.2)
APC 19.077 7/14 (50, 23.0–77.0) 5/43 (11.6, 3.9–25.1)
RAR-b2 14.273 3/14 (21.4, 4.7–50.8) 1/43 (2.3, 0.1–12.3)
VGF 0.023 7/14 (50, 23.0–77.0) 7/43 (16.3, 6.8–30.7)
ER-a 72.072 5/14 (35.7, 12.8–64.9) 8/43 (18.6, 8.4–33.4)
ER-b 10.145 9/14 (64.3, 35.1–87.2) 12/43 (27.9, 15.3–43.7)
FKBP4 35.001 5/14 (35.7, 12.8–64.9) 1/43 (2.3, 0.1–12.3)
Abbreviation: CI¼ confidence interval.
Table 5b Seminomas and non-seminoma testicular samples: (b) analysis
of gene panels, based on logistic regression model, considering optimal
cutoff for differenciating both groups
Combined
genes
Cutoff
based on
predictive
probability
of tumora
Sensi-
tivity (%)
Speci-
ficity (%)
AUC
(95% CI)
APC 0.3644 78.6 (49.2 – 95.3) 90.7 (77.9 – 97.4) 0.87 (0.74 – 0.99)
APC, MLH1,
ER-b and FKBP4
0.124726 85.7 (57.2 – 98.2) 93.0 (80.9 – 98.5) 0.90 (0.81 – 1.00)
Abbreviations: AUC¼ area under the curve; CI¼ confidence interval. aPredictive
probabilities were obtained from the logistic regression models.
Promoter hypermethylation, testicular cancer, biomarkers
M Brait et al
418
British Journal of Cancer (2012) 106(2), 414 – 423 & 2012 Cancer Research UK
G
e
n
e
tic
s
a
n
d
G
e
n
o
m
ic
s
genes analysed throughout the testicular tissues are shown in
Figure 1.
Association between DNA methylation changes and
clinicopathological factors
There were no apparent correlations between any of the gene
tested with any clinicopathological parameters, including age, site,
race and disease stages, perhaps due to the limited number of
sample size (data not shown). As shown before, we found
differential methylation patterns in two different histological types
(SEs and NSEs). Methylation values were compared as continuous
variables, as well as dichotomised, and no correlation was
observed in either analysis.
DISCUSSION
In this study, we attempted to define a set of methylation markers
that would allow for an accurate discrimination among the two
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Figure 1 Representative scatter plots of methylation values of tested genes in seminomas, non-seminomas and normal testis samples. Genes: AIM1, ARF,
CCNA1, MGMT, hMLH1, PGP9.5, S100A2, APC, RAR-b2, ER-a, ER-b, MCAM, VGF, FKBP4 and SSBP2. Calculation of the gene of interest: ratios were based
values for both the gene of interest and b-actin obtained by quantitative real-time PCR analysis. The obtained ratios were multiplied by 1000 for easier
tabulation. Values designated as 0.1 are 0 values, which cannot be plotted correctly on a log scale.
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most common types of TGCT (SE and NSE); as each type displays
dissimilar clinical behaviour and successful pre-operative cytolo-
gical or histological assessment is restricted. Through gene
promoter methylation profiling with QMSP, six genes were found
to be differentially methylated in the two tumour types.
In particular, higher PGP9.5 methylation frequency was detected
in SEs than NSEs, whereas high methylation frequency of MGMT,
VGF, ER-b and FKBP4 were associated with NSE. Remarkably,
both SE and NSE were methylated for APC and hMLH1. Netto et al
(2008) showed evidence that SEs remain unmethylated, whereas
the other histological types arise after de novo methylation,
suggesting that they may arise in distinct periods of the
development process of the germ cells, and that their genome
methylation status may determine the degree of differentiation
of the cells. Wermann et al (2010) also observed the same pattern
of all SEs being unmethylated (as well as tumours of similar
histology originating in other organs), whereas NSEs were
consistently hypermethylated. Koul et al, (2002), using conven-
tional MSP, analysed a panel of 21 genes and observed a near
absence of methylation in SEs and a higher percentage in NSEs,
suggesting a role for different panel of methylation-induced
inactivation of TSGs in two common types of TGCT. Similar to
our results, they also observed presence of methylation in the
MGMT promoter in NSEs (21 vs 14% observed in this study) and
absence in SEs. The other two genes that showed this same pattern
were not evaluated by our study (BRCA1 and RASSF1A), and their
panel did not include the other genes observed to be methylated in
NSEs vs SEs (VGF, ER-b and FKBP4). Subtype-specific patterns of
global methylation were also previously reported in TGCT
(Smiraglia et al, 2002). Peltomaki (1991) observed hypomethyl-
ation in SEs, whereas NSEs were largely hypermethylated. The
same observation was made in studies of the X chromosome
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(Looijenga et al, 1997). In breast cancer, Lehmann et al (2002)
observed that the presence of promoter methylation in DAPK was
frequent in invasive lobular cancer (53%) and not frequent in
another histological subtype (9% invasive ductal carcinoma).
Other reports that include different epigenetic alterations in
histological subtypes of the same cancer type include: presence
of methylator phenotype in low-grade gliomas when compared
with de novo glioblastomas (Laffaire et al, 2011), high frequency of
SFN methylation in small cell lung cancer, whereas a rare
frequency in non-small cell lung cancer (Osada et al, 2002).
Consistent with epigenetic heterogeneity, there is a wide search for
genetic alterations that would be able to distinguish SEs and NSEs.
Coffey et al (2008) reported that Kit mutations are predominant in
SEs and very rarely observed in NSEs. Major accentuated genetic
differences are yet to be discovered.
Previous studies did indicate a role for hypermethylation of TSG
promoters in the pathogenesis of SE. In our data, when comparing
SEs versus NT samples, the genes that showed higher frequency of
methylation in SE were PGP9.5, hMLH1 and ER-b, when compared
with the observed frequency in normal samples. In combination,
the strongest pair is APC and MCAM, showing 78.3% frequency in
tumours and 23.3% in normals. With the same cutoff, adding
hMLH1, the frequency in tumours was 79.1%, and adding both
AIM1 and PGP9.5, or only one of them, it increases to 81.4%, with
the same percentage in normals (23.3%). This panel containing
four genes showed reasonable percentages to distinguish normal
and tumour tissue.
MCAM had not been previously evaluated in TGCT. In prostate
cancer, other showed 85% methylation in tumours vs 0% in normal
prostate (Hoque et al, 2008). To our knowledge, PGP9.5 and AIM1
had not been analysed in this tumour type. APC was previously
observed with 10% of methylation in tumours and 0% in NT, but
both positive tumours were NSE (Koul et al, 2002), and no APC
methylation has been reported in Ses; it is important to emphasise
that this study was performed using conventional MSP, a less
sensitive technique than QMSP used in the present study (Hoque
et al, 2004), which may explain the different percentages observed.
In this same study, hMLH1 showed only 4% methylation in
tumours and 0% in normals, occurring in both SEs and NSEs.
In respect to the comparison between NSEs and normals, there
are two genes (MGMT and VGF) that stand out alone, both with a
0% frequency in normals and 50% frequency in NSEs. VGF is a
gene recently reported to be methylated in cancer by our group
(Hoque et al, 2008) and had never been analysed in TGCT. MGMT
had been reported to be frequently methylated in TGCT (Smith-
Sorensen et al, 2002), showing 69% in NSEs. In 2004, Koul et al
(2004) showed methylation in MGMT in 20% of NSEs analysed by
conventional MSP, a less sensitive technique as mentioned earlier.
Using empiric cutoffs, at least one of the three genes (hMLH1,
APC and ER-b) was methylated in 13 out of 14 (93%) of NSE cases
and 10 out of 23 (43%) of the NT samples. Previously reported
methylation of APC and hMLH1 were 10% to less than 5%,
respectively (Koul et al, 2002). There are no reported studies
exploring methylation status of ER-b in TGCT. The downregula-
tion of ERb was observed in SEs by Esposito et al (2010); they
detected decreased expression of ERb protein in SEs when
compared with NT, but they did not evaluate promoter methyla-
tion. This gene encodes a member of the family of oestrogen
receptors and superfamily of nuclear receptor transcription
factors. The gene product contains an N-terminal DNA-binding
domain and C-terminal ligand-binding domain, and is localised to
the nucleus, cytoplasm and mitochondria. It is able to interact with
specific DNA sequences to activate transcription. Some isoforms
dominantly inhibit the activity of other oestrogen receptor family
members.
Epigenetic inactivation of hMLH1 is found in a wide range of
cancers. hMLH1 is a DNA mismatch repair (MMR) gene and is an
essential component of the DNA MMR pathway, and is frequently
mutated in hereditary non-polyposis colon cancer also known as
Lynch syndrome. Activation of the MMR pathway may trigger
DNA damage signalling, a process which induces cell cycle arrest
and can lead to cell death in case of major DNA damages
(for review, please see Jiricny (2006)). hMLH1 is the most
prominent target of epigenetic silencing in the MMR pathway in
sporadic tumours, comprising ovarian, head and neck, breast and
colorectal cancer (Herman et al, 1998). However, hypermethyla-
tion of hMLH1 is often associated with other hypermethylated
genes, which complicates mechanistic interpretation of associa-
tions with response to therapy in patients (Shen et al, 2007).
Mechanistic investigations using in vitro system have shown that
treatment of hMLH1-methylated colon cancer cell lines with the
demethylating agent 5aza-2deoxycytidine (5-aza-dC) restores
hMLH1 expression and subsequently renders the cells MMR
proficient (Herman et al, 1998).
Promoter methylation of hMLH1 has been associated with
chemoresistance to cisplatin-based therapies in ovarian cancer
more than a decade ago (Strathdee et al, 1999). In our study, both
SEs and NSEs displayed methylation in this locus, 27% and 71%,
respectively. It is well established that NSE and SE (all TGCT) are
widely responsive to cisplatin-based therapy (Bosl and Motzer,
1997), so one wouldn’t expect the high presence of hMLH1
methylation in this tumour type. Olasz et al (2005) hypothesised
that this epigenetic alteration could be linked to the chemoresis-
tance in a small group of testicular tumours, but could not observe
any association. On the other hand, Honecker et al. (2009)
investigated a larger cohort and observed that lack or low
expression of hMLH1 (on the protein level) was significantly
associated with cisplatin-resistant TGCTs, and the absence of
expression was also correlated with presence of hMLH1 promoter
methylation. Probably the mechanisms of resistance/sensitivity to
this chemothepeutic agent are different among the ovarian and
TGCT. It is widely accepted that hMLH1 dysfunction induces
microsatellite instability (MSI) in various cancers, and loss of
hMLH1 expression was related to its promoter methylation.
However, no correlation was observed between hMLH1 methyla-
tion and MSI in TGCTs (Olasz et al, 2005). In our study, hMLH1
methylation was detected in 22 out of 57 (39%) of TGCTs.
However, we did not perform expression or MSI analysis in these
samples; therefore, we are not able to correlate hMLH1 methyla-
tion with expression and MSI. Esteller et al (2000) reported that
promoter methylation of MGMT results in enhanced sensitivity to
alkylating agents in gliomas. In the present study, MGMT was
highly methylated in NSEs, which could indicate that the
epigenetic silencing of this gene may be also linked to the
cisplatin-based chemotherapy response, but this data needs to be
further explored in a well-defined cohort consisting of cisplatin
responsive group and non-responsive group.
Silencing TSG by DNA promoter methylation is an important
feature of cancer. It is known that cancer types may vary in their
epigenetic profiles in a tissue-specific pattern (Esteller et al, 2001).
We used a candidate gene approach to test 15 promoter regions in
a testicular cohort; all the markers evaluated here have shown
differential methylation in malignant vs benign tissues in several
cancer types (Hoque et al, 2008). Our data shows different patterns
of methylation not only between tumours and normal, but also
between the two histological subtypes of germ cell tumours. These
distinct promoter methylation profiles of the two main subtypes of
germ cell testicular cancer, SEs and NSEs, may shed a light on how
they develop and differentiate from the same cell of origin.
In conclusion, our study constitutes a comprehensive profile of
hypermethylated genes in testicular tissues. Several of genes tested
in this study were not evaluated for promoter methylation in this
cancer types before, which may partially be due to rarity of
the disease and limited number of samples. The observation of the
higher proportion of promoter methylation of putative and
established TSGs in NSEs when compared with SEs may enrich
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our knowledge of this tumour type. Further study using larger
cohorts is needed to evaluate the potential use of these methylation
markers in the detection, prognosis and therapeutic outcome of
this rare tumour.
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